Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.

JM, Kremer; CO 3rd, Bingham; LC, Cappelli; JD, Greenberg; AM, Madsen; J, Geier; JL, Rivas; AM, Onofrei; CJ, Barr; DA, Pappas; HJ, Litman; KJ, Dandreo; AB, Shapiro; CA, Connell; A, Kavanaugh

doi:10.1002/acr2.11232

Public

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.

Shared by NobleBlocks on Feb 11, 2021 • 12:00 AM UTC

Authors:

Kremer JM

Bingham CO 3rd

Cappelli LC

Abstract

<h4>Objective</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-modifying antirheumatic drugs (bDMARDs) with...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!